Boeing Halts Cash Drain but Takes $4.9B Hit on 777X Delays

Boeing (NYSE: BA) managed to turn the cash flow tide in its favor for the first time since late 2023, ending a nearly two-year stretch of burning cash. However, the aerospace giant acknowledged a hefty $4.9 billion charge related to continued postponements of its 777X wide-body aircraft, a program still seeking final regulatory clearance after nearly six years.

Chief Executive Officer Kelly Ortberg, who took over the reins in August 2024, has focused on shoring up Boeing's shaky supply chains and improving production reliability. This effort supported a delivery ramp-up, putting the company on track to match its highest plane deliveries since 2018, a milestone that signals regained momentum after several challenging years.

While Boeing's third-quarter revenue surged 30% year-over-year to $23.27 billion-beating expectations-the company still reported a net loss of $4.78 billion ($7.14 per share). Adjusted losses widened to $7.47 per share, exceeding analyst predictions, revealing the ongoing cost pressures and complications dogging the company.

The 777X program remains the elephant in the room. Its first flight was back in 2019, but regulatory approvals have stalled final deliveries, which Boeing now predicts won't happen until 2027. This delay forced the company to take the noncash impairment charge, highlighting the program's stressed timeline and budget.

Despite setbacks, Boeing's commercial aircraft segment revenue jumped 49% to $11.09 billion in Q3, though profitability still eludes that unit. Its defense sector produced $6.9 billion in revenue with slim operating margins amid ongoing labor strikes involving around 3,200 workers, further complicating operational stability.

Meanwhile, free cash flow turned positive with $238 million generated, a notable turnaround after nearly two years of cash hemorrhaging. Airline customers report improved delivery accuracy and timeliness, a sharp contrast to past years riddled with delays and uncertainty.

Boeing's Max 7 and Max 10 variants are also lagging years behind schedule, putting pressure on the company's ability to fully recover its commercial product lineup. The FAA's recent moves-lifting production caps on the 737 Max and granting Boeing more autonomy in final inspections-signal cautious regulatory trust returning.

Yet with ongoing labor disputes, regulatory hurdles, and program delays, Boeing's path to a full recovery seems far from straightforward. The big question remains: can the 777X finally take off and validate Boeing's turnaround bets, or will this remain an expensive delay on the balance sheet?